Nanoparticle development 'could improve cancer treatment'

20 September 2011

The development of a new type of nanoparticle could show increased potential of using chemotherapy to treat cancer patients.

A study at the University of North Carolina led by Wenbin Lin showed that a new type of nanoparticle can deliver larger amounts of a drug and will not leak the medication as the particle circulates through the blood stream on its way to the target cancerous cells.

In tests, Mr Lin and his colleagues tested the nanoparticle's ability to deliver the chemotherapy drug oxaliplatin to tumours in the colon and pancreas, cancers that are renowned as difficult to treat. The team found that the nanoparticle has two to three times greater therapeutic efficacy over oxaliplatin.

Mr Lin said: "The polysilsesquioxane particle we have developed carries extremely high loadings of oxaliplatin-based chemotherapeutics. The particles are stable under normal physiological conditions, but can be readily reduced to release the platin cargoes."

He added that the nanoparticle is able to release the drug in a controlled fashion.

Oxaliplatin was discovered in 1976 at Nagoya City University by Professor Yoshinori Kidani.

Posted by Jeanette Royston

Wenbin, Lin et al., Angewandte Chemie September 14th 2011.

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)